Hantavirus infection: Difference between revisions
No edit summary |
m (Bot: Removing from Primary care) |
||
(21 intermediate revisions by 10 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hantavirus | {{About1|Hantavirus}} | ||
{{CMG}} | '''For patient information, click [[Hantavirus infection (patient information)|here]]''' | ||
{{Hantavirus infection}} | |||
{{CMG}}; {{AE}} {{ADG}} {{USAMA}} {{SMP}} {{MMF}} | |||
{{SK}} Sin nombre virus | {{SK}} Sin nombre virus infection; Hantavirus cardiopulmonary syndrome (HCPS); Nephropathia epidemica (NE); Hemorrhagic fever with renal syndrome (HFRS) | ||
== [[Hantavirus | == [[Hantavirus infection overview|Overview]] == | ||
== [[Hantavirus | == [[Hantavirus infection historical perspective|Historical Perspective]] == | ||
== [[Hantavirus infection classification|Classification]] == | |||
== [[Hantavirus | == [[Hantavirus infection pathophysiology|Pathophysiology]] == | ||
== [[Hantavirus pulmonary syndrome | == [[Hantavirus infection differential diagnosis|Differentiating Hantavirus pulmonary syndrome from other Diseases]] == | ||
== [[Hantavirus | == [[Hantavirus infection epidemiology and demographics|Epidemiology and Demographics]] == | ||
== [[Hantavirus | == [[Hantavirus infection risk factors|Risk Factors]] == | ||
== [[Hantavirus infection natural history, complications and prognosis|Natural History, Complications and Prognosis]] == | |||
== Diagnosis == | == Diagnosis == | ||
[[Hantavirus | [[Hantavirus infection history and symptoms|History and Symptoms]] | [[Hantavirus infection physical examination|Physical Examination]] | [[Hantavirus infection laboratory findings|Laboratory Findings]] | [[Hantavirus infection chest x ray|Chest X Ray]] | [[Hantavirus infection other imaging findings|Other Imaging Findings]] | [[Hantavirus infection other diagnostic studies|Other Diagnostic Studies]] | ||
== Treatment == | == Treatment == | ||
[[Hantavirus | [[Hantavirus infection medical therapy|Medical Therapy]] | [[Hantavirus infection surgery|Surgery]] | [[Hantavirus infection primary prevention|Primary Prevention]] | [[Hantavirus infection secondary prevention|Secondary Prevention]] |[[Hantavirus infection cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Hantavirus infection future or investigational therapies|Future or Investigational Therapies]] | ||
==Case Studies== | ==Case Studies== | ||
[[Hantavirus | [[Hantavirus infection case study one|Case #1]] | ||
== Acknowledgements == | == Acknowledgements == | ||
Line 39: | Line 43: | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Viral diseases]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Emergency mdicine]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category:Nephrology]] | |||
[[Category:Cardiology]] | |||
[[Category:Pulmonology]] |
Latest revision as of 21:57, 29 July 2020
For patient information, click here
Hantavirus infection Microchapters |
Patient Information |
---|
Diagnosis |
Treatment |
Case Studies |
Hantavirus infection On the Web |
American Roentgen Ray Society Images of Hantavirus infection |
Directions to Hospitals Treating Hantavirus pulmonary syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2] Usama Talib, BSc, MD [3] Seyedmahdi Pahlavani, M.D. [4] Furqan M M. M.B.B.S[5]
Synonyms and keywords: Sin nombre virus infection; Hantavirus cardiopulmonary syndrome (HCPS); Nephropathia epidemica (NE); Hemorrhagic fever with renal syndrome (HFRS)
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Hantavirus pulmonary syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention |Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies
Acknowledgements
The content on this page was first contributed by: C. Michael Gibson, M.S., M.D. List of contributors: Pilar Almonacid